Moderna Inc MRNA shares are trading higher Monday after the company announced its bivalent Omicron-targeting booster candidates showed a superior antibody response compared to a booster dose of its prototype vaccine in Phase 2/3 clinical trials.
Moderna said its booster candidates, mRNA-1273.214 and mRNA-1273.222, triggered a superior antibody response compared to a booster dose of mRNA-1273. Both bivalent vaccines also met non-inferiority immunogenicity criteria to the original strain.
“We are pleased to see that both of our bivalent booster vaccine candidates offer superior protection against Omicron BA.4/BA.5 variants compared to our original booster, which is encouraging given COVID-19 remains a leading cause of hospitalization and death globally. In addition, the superior response against Omicron persisted for at least three months after the mRNA-1273.214 booster,” said Stéphane Bancel, CEO of Moderna.
Moderna said it will submit the safety and immunogenicity data for peer-reviewed publication. It also plans to share the data with regulators globally.
See Also: What’s Going On With Biogen Stock Today?
MRNA Price Action: Moderna has a 52-week high of $249.42 and a 52-week low of $115.03.
The stock was up 6.14% at $181.71 at time of publication, according to Benzinga Pro.
Photo: Marco Verch from Flickr.
Image and article originally from www.benzinga.com. Read the original article here.